Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01911455 · ClinicalTrials.gov registry record · Phase 1
Study of Acamprosate in Fragile x Syndrome
A Phase 1 study, sponsored by Children's Hospital Medical Center, Cincinnati.
- Completed
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
NCT01911455 is a Phase 1 study that has completed, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 46 participants.
The verdict
NCT01911455, a Phase 1 study, has completed, sponsored by Children's Hospital Medical Center, Cincinnati.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
Study Summary
In this research study we want to understand the effectiveness of a drug treatment, acamprosate, for interfering symptoms (i.e., inattention/hyperactivity, social impairment) associated with Fragile X Syndrome (FXS).
Interventions
- DRUG Placebo
- DRUG acamprosate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2013-08-27 |
| Est. Completion | 2018-11-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01911455
The ClinicalTrials.gov registry entry for NCT01911455 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Hospital Medical Center, Cincinnati, which has 571 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01911455 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01911455 about?
NCT01911455 is a clinical study titled "Study of Acamprosate in Fragile x Syndrome". In this research study we want to understand the effectiveness of a drug treatment, acamprosate, for interfering symptoms (i.e., inattention/hyperactivity, social impairment) associated with Fragile X Syndrome (FXS).
What is the current status of trial NCT01911455?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2013-08-27. Estimated completion is 2018-11-08.
What interventions are being tested in trial NCT01911455?
The interventions under investigation include: Placebo (DRUG), acamprosate (DRUG).
Who is sponsoring clinical trial NCT01911455?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.